Introduction
Toll-like receptors (TLRs) are members of a family of receptors encoded by different TLR genes (TLR1-13) that are expressed in many tissues and cell types and participate in antigen recognition. The participation of TLRs in the activation of the innate immune response suggests their possible role as candidate genes in the development of autoimmune diseases [1] .
Human Toll-like receptor 4 (TLR4) gene is located on chromosome 9q32-q33, and contains four exons. Toll-like receptor 4 encodes a major endotoxin signaling receptor that plays a fundamental role in pathogen recognition and activation of innate immunity. Two non-synonymous SNPs rs498690 (A896G) and rs4986791 (C1196T) in exon 3 lead to Asp299Gly and Thr399Ile amino acid substitutions, respectively. These SNPs are located in the coding sequence, affect TLR-4 extracellular domain. Individuals possessing a co-segregating polymorphism in TLR-4 (Asp299Gly and Thr399Ile) are hyporesponsive to LPS and are more susceptible to Gram-negative bacterial infections [2, 3] . In Asian populations, the prevalence of rs498690 and rs4986791 is very low. Several studies have demonstrated the absence of rs498690 and rs4986791 in the Chinese population [4] [5] [6] and in the Korean population [7] .
In fact, in previous meta-analyses TLR4 polymorphisms appeared to be correlated with Crohn's disease, ulcerative colitis [8] , vasculitis [9] and cancer [10] , but not with sepsis [11] , rheumatoid arthritis, ankylosing spondylitis [12] [13] [14] , and atherosclerosis [15] . To date, a number of molecular epidemiological studies have been done to evaluate the association between TLR4 Asp299Gly and Thr399Ile polymorphisms and several autoimmune diseases (ADs) including type 1 diabetes (T1DM) [16] , celiac disease (CED) [16, DOI: 10.5114/ceji.2013.37757 17], rheumatoid arthritis (RA) [18] [19] [20] [21] , multiple sclerosis (MS) [22, 23] , and systemic lupus erythematosus (SLE) [19] in Caucasians. However, the results remained inconsistent.
Considering that a relatively lower frequency of the minor allele and a single study might have been underpowered to detect the overall effects, quantitative syntheses of the accumulated data from different studies were deemed important to provide evidence on the associations of TLR4 Asp299Gly and Thr399Ile polymorphisms and ADs risk. So, we carried out this meta-analysis on all published case-control studies to estimate the overall ADs risk of Asp299Gly and Thr399Ile polymorphisms and to quantify heterogeneity between the individual studies as well as to investigate the existence of a potential publication bias.
Material and methods

Publication search and inclusion criteria
We searched the PubMed, Embase, CNKI (China National Knowledge Infrastructure) databases for all articles within a range of published years from 2000 to 2012 on the association between TLR4 Asp299Gly and Thr399Ile polymorphisms and ADs risk (last search was updated on 20 October 2012). The following terms were used in this search: 'Toll-like receptor-4 or TLR4' and 'autoimmune disease or type 1 diabetes or celiac disease or rheumatoid arthritis or multiple sclerosis or Grave's disease or Wegener's granulomatosis or psoriasis or primary sicca syndrome or systemic lupus erythematosus or inflammatory bowel disease' and 'polymorphism or polymorphisms'. In order to identify the relevant publications, the references cited in the research papers were also scanned.
Studies testing the association between TLR4 Asp299Gly and Thr399Ile polymorphisms and ADs risk were included if all of the following conditions were met: (a) the publication was a case-control study; (b) evaluation of the association of TLR4 Asp299Gly and/or Thr399Ile polymorphisms and ADs risk; (c) the ADs diagnosis complied with the diagnosis criteria of the World Health Organization (WHO); (d) the study reported OR or data for their calculation; and (e) the study was published in English.
Data extraction
Data from these studies were extracted by Xiao-qin Wang and Kui Zhang. Publications were read by Xiao-qin Wang in order to check original data extraction. Finally, the data for this meta-analysis were available from eight casecontrol studies for the Asp299Gly polymorphism, including 3317 cases and 3131 controls, and three studies were available for the Thr399Ile polymorphism, including 815 cases and 479 controls (as shown in Fig. 1 ). The following information was recorded for each study: first author, year of publication, region, number of alleles, number of genotypes, genotyping methods, disease, frequencies of minor allele in control subjects, and evidence of Hardy-Weinberg Equilibrium (HWE) in control subjects (all of the data are shown in Table 1 ).
Statistical analysis
The OR corresponding to the 95% confidence interval (95% CI) was used to assess the association between TLR4 Asp299Gly and Thr399Ile polymorphisms and risk of ADs. We evaluated the risk of the minor allele on ADs compared with the major allele and then calculated the OR of minor allele carriers versus major allele homozygous using a dominant genetic model of the minor allele.
The statistical heterogeneity among studies was assessed with the Q-test and I 2 statistics [24] . If there was no obvious heterogeneity, the fixed-effects model (the MantelHaenszel method) was used to estimate the summary OR [25] ; otherwise, the random-effects model (the DerSimonian and Laird method) was used [26] . To explore sources of heterogeneity across studies, we did logistic meta-regression analyses. We examined the following study characteristics: publication year, region, genotyping, disease, number of alleles, number of genotypes, and minor allele frequency in controls. The HWE was assessed by Fisher's exact test (significance set at p < 0.10). Publication bias was evaluated with funnel plot and Begg's rank correlation method [27] . The statistical analyses were performed by STATA 12.0 software (StataCorp., CollegeStation, TX).
Results
Characteristics of studies
Overall, eight case-control studies were available for the Asp299Gly polymorphism, including 3317 cases and 3131 controls, and three studies were available for the Thr399Ile polymorphism, including 815 cases and 479 controls. Study characteristics are summarized in Table 1 . Three genotyping methods were used, including polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), TaqMan probe, and direct sequencing. The diseases included type 1 diabetes, celiac disease, rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus. The genotype distributions among the controls were consistent with HWE except the one performed by Kilding et al. [18] .
Quantitative synthesis
For control subjects, G allele frequency of TLR4 Asp299Gly polymorphism was ranging from 0.047 to 0.086, T allele frequency of TLR4 Thr399Ile polymorphism was ranging from 0.068 to 0.070. The evaluations of the association of TLR4 Asp299Gly polymorphism and TLR4 Thr399Ile polymorphism with ADs risk are shown in Table 2 , Fig. 2 and Fig. 3 , respectively. The TLR4 Asp299Gly and TLR4 Thr399Ile polymorphisms were not associated significantly with a risk of ADs (O Asp299Gly: R = 0.86, 95% CI: 0.74-1.00 for G vs. A and OR = 0.87, 95% CI: 0.74-1.01 for AG/GG vs. AA, respectively; Thr399Ile: OR = 0.77, 95% CI: 0.57-1.05 for T vs. C and OR = 0.79, 95% CI: 0.58-1.09 for TT/CT vs. CC, respectively). Furthermore, stratified analyses failed to find the TLR4 Asp299Gly polymorphism significantly associated with CED, RA, and MS (as shown in Fig. 2 ).
Evaluation of heterogeneity
There was no obvious heterogeneity among studies in overall comparisons (P heterogeneity = 0.372, I 2 = 7.6% in allele comparison for the TLR4 Asp299Gly polymorphism, P heterogeneity = 0.224, I 2 = 23.8% in dominant genetic model comparison for the TLR4 Asp299Gly polymorphism, P heterogeneity = 0.785, I 2 = 0% in allele comparison for the TLR4 Thr399Ile polymorphism, and P heterogeneity = 0.716, I 2 = 0% in dominant genetic model comparison for the TLR4 Thr399Ile polymorphism, respectively). 
Fig. 2. Forest plot of ADs associated with distribution of TLR4 Asp299Gly polymorphism
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Sensitivity analysis
The influence of a single study on the overall meta-analysis estimate was investigated by omitting one study at a time, and the omission of any study made no significant difference, indicating that our results were statistically reliable.
Publication bias
The Begg's test was performed to evaluate the publication bias of selected literature items. Figure 4 displays a funnel plot that examined both the polymorphisms and overall ADs risk included in the meta-analysis. No evidence of publication bias in our study was observed (P = 0.210 for the TLR4 Asp299Gly polymorphism and P = 0.308 for the TLR4 Thr399Ile polymorphism).
Discussion
Previous meta-analysis indicated that TLR4 polymorphisms appeared to be correlated with Crohn's disease, ulcerative colitis [8] , vasculitis [9] and cancer [10] , but not with sepsis [11] , rheumatoid arthritis, ankylosing spondylitis [12] [13] [14] , and atherosclerosis [15] . In the present study, we performed a systematic review of the association between TLR4 Asp299Gly and Thr399Ile polymorphisms and the risk of ADs. We searched PubMed, Embase, CNKI databases for all articles on the association between TLR4 polymorphisms and ADs, including type 1 diabetes, celiac disease, rheumatoid arthritis, multiple sclerosis, Grave's disease, Wegener's granulomatosis, psoriasis, primary sicca syndrome, and systemic lupus erythematosus. Finally, eight case-control studies were available for the Asp299Gly polymorphism, including 3317 cases and 3131 controls, and three studies were available for the Thr399Ile polymorphism, including 815 cases and 479 controls. Among the eight case-control studies available for the Asp299Gly polymorphism, one study was concerned with T1DM [16] , two were concerned with CED [16, 17] , four were concerned with RA [18] [19] [20] [21] , two were concerned with MS [22, 23] , and one was concerned with SLE [19] . Our results showed that The TLR4 Asp299Gly and TLR4 Thr399Ile polymorphisms were not associated significantly with a risk of ADs both in allele comparison and in dominant genetic model comparison. Furthermore, stratified analyses failed to find the TLR4 Asp299Gly polymorphism significantly associated with CED, RA, and MS.
The TLR4 is known to activate the NF-κB and subsequent gene expression such as cytokines and adhesion molecules [28] [29] [30] [31] [32] . Through the recognition of pathogens or their products, TLR4 can induce the production of proinflammatory cytokines that can contribute to the perpetuation of the inflammatory response. It is accepted that activation of the innate immune system is an important feature in the pathogenesis of Ads [33] [34] [35] . These two selected non-synonymous SNPs are located in the coding sequence, affect TLR-4 extracellular domain. Individuals possessing a co-segregating polymorphism in TLR-4 (Asp299Gly and Thr399Ile) are hyporesponsive to LPS and are more susceptible to Gram-negative bacterial infections [2, 3] .
Previous studies found these two selected polymorphisms in Mexico [36] and India [37, 38] . In Asian populations, the prevalence of rs498690 and rs4986791 is very low. Several studies have demonstrated the absence of rs498690 and rs4986791 in the Chinese population [4] [5] [6] and in the Korean population [7] . We researched the PubMed, Embase, CNKI (China National Knowledge Infrastructure) databases for all articles on the association between TLR4 Asp299Gly and Thr399Ile polymorphisms and ADs risk, the results showed that all available articles are related to Caucasians.
Among all the available articles, one epidemiological study found that the TLR4 Asp299Gly polymorphism was associated with a decreased RA risk [21] , but others failed to find the same result. Our study with accumulated data from different studies suggested that TLR4 Asp299Gly and Thr399Ile polymorphisms may not be associated with an ADs risk. Since only 8 case-control studies were available for this analysis until recently, further studies using large numbers of participants should be conducted to validate the association.
Our study evaluated the heterogeneity; there was no obvious heterogeneity among studies in overall comparisons. The influence of a single study on the overall metaanalysis estimate was investigated by omitting one study at a time, and the omission of any study made no significant difference, indicating that our results were statistically reliable. The Begg's test denied the publication bias in our study. No evidence of publication bias in our study was observed (P = 0.210 for the TLR4 Asp299Gly polymorphism and P = 0.308 for the TLR4 Thr399Ile polymorphism).
The data included in the present meta-analysis have some limitations: (1) all the enrolled studies only included the association of selected polymorphisms with ADs, further studies estimating the effect of gene-gene and geneenvironment interactions may eventually provide a better, comprehensive understanding; (2) due to the low frequency of the minor allele, it is difficult for analyses by using any more genetic models.
In conclusion, this meta-analysis suggested that TLR4 Asp299Gly and TLR4 Thr399Ile polymorphisms were not involved in the development of ADs. However, welldesigned studies with a larger sample size should be conducted to confirm this result. Moreover, further studies estimating the effect of gene-gene and gene-environment interactions may eventually provide a better, comprehensive understanding.
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